Sugi Predict

Sugi Predict / Compounds / SCHEMBL127712

SCHEMBL127712

SCHEMBL127712

[CH2]CC(O)C1CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.56
▸ SMN1; SMN2 Q16637 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ GMNN O75496 1/20 0.56
▸ MAPT P10636 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ PMP22 Q01453 1/20 0.56
▸ EPHX1 P07099 3/20 0.39
▸ SHBG P04278 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ HTT P42858 1/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ MEN1 O00255 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8358942 1.00 TP53 (0.58) TP53KDM4ESMN1; SMN2LMNAGMNN
SCHEMBL128735 0.97 — —
SCHEMBL128106 0.92 — —
SCHEMBL129097 0.86 — —
SCHEMBL7507508 0.80 TP53 (0.54) TP53KDM4ESMN1; SMN2LMNAGMNN
SCHEMBL7287995 0.80 TP53 (0.54) TP53KDM4ESMN1; SMN2LMNAGMNN
SCHEMBL5185757 0.78 TP53 (0.64) TP53KDM4ESMN1; SMN2LMNAGMNN
SCHEMBL14463100 0.78 TP53 (0.64) TP53KDM4ESMN1; SMN2LMNAGMNN
SCHEMBL6227823 0.78 TP53 (0.64) TP53KDM4ESMN1; SMN2LMNAGMNN
SCHEMBL7285118 0.77 TP53 (0.50) TP53KDM4ESMN1; SMN2LMNAGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140828-B1 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS PFIZER LTD (GB) 2006-08-09 — — EP claimed
CN-1192021-C 3-azabicyclo [3.1.0] hexane derivatives as opioid receptor ligands PFIZER LTD (US) 2005-03-09 — — CN claimed
EP-1077940-B1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER (US) 2004-07-14 — — EP claimed
US-6610711-B2 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-08-26 — — US claimed
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses PFIZER INC. 2003-04-24 — — US claimed
US-20030013875-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy PFIZER, INC. (US) 2003-01-16 — — US claimed
US-20020072616-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy PFIZER INC. 2002-06-13 — — US claimed
CN-1331679-A 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands PFIZER LTD (US) 2002-01-16 — — CN claimed
US-6313312-B1 OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING PFIZER INC 2001-11-06 — — US claimed
EP-1140828-A1 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS Pfizer Limited (GB) 2001-10-10 — — EP claimed
EP-1077940-A1 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER INC. (US) 2001-02-28 — — EP claimed
WO-2000039089-A1 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS PFIZER LIMITED (GB) 2000-07-06 — — WO claimed
WO-1999059971-A1 NOVEL 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES PFIZER INC. (US) 1999-11-25 — — WO claimed
EP-0046597-A1 2,4-Diazabicyclo(3.3.0)octane-3-one derivatives, their preparation and their pharmaceutical formulation THE WELLCOME FOUNDATION LIMITED (GB) 1982-03-03 — — EP claimed
EP-3820836-A1 COMPOSITIONS OF OXYGENATED AMINES AND QUINONE METHIDES AS ANTIFOULANTS FOR VINYLIC MONOMERS Ecolab USA, Inc. (US) 2021-05-19 — — EP disclosed
CN-112513005-A Amine oxide and methylated quinone combination as an antifoulant for ethylene monomers 埃科莱布美国股份有限公司 2021-03-16 — — CN disclosed
CN-108008600-B Radiation-sensitive composition 三菱瓦斯化学株式会社 2021-02-09 — — CN disclosed
US-4851387-A RENIN INHIBITORS BANYU PHARMACEUTICAL CO., LTD. (JP) 1989-07-25 — — US disclosed
EP-0272583-A2 5-Substituted amino-4-hydroxy-pentenoic acid derivatives and their use Banyu Pharmaceutical Co., Ltd. (JP) 1988-06-29 — — EP disclosed
EP-0264106-A2 5-Substituted amino-4-hydroxy-pentanoic acid derivatives and their use Banyu Pharmaceutical Co., Ltd. (JP) 1988-04-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072616-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy OPRM1, OPRK1, OPRD1 TP53 3998/4885KDM4E 3058/4885SMN1; SMN2 2757/4885
US-20030078282-A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses HRH2, HRH4, HRH1 TP53 4781/4885KDM4E 1226/4885SMN1; SMN2 4043/4885
US-20030013875-A1 3-azabicyclo[3.1.0]hexane derivatives useful in therapy OPRM1, OPRK1, OPRD1 TP53 3998/4885KDM4E 3058/4885SMN1; SMN2 2757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.